Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study of Ustekinumab in patients ...

Sands, BE; Gasink, C; Gao, L-L; More

Inflammatory Bowel Diseases . 17:S24, December 2011.